Vaccination Strategies Impact: India’s Maximising Immunisation Benefit

By Staff Writer

April 14, 2024

Introduction

Vaccinations stand as a testament to public health triumphs, yet the journey to universal coverage remains fraught with challenges. In 2022, a stark 11% of children globally missed out on vital vaccines, such as the diphtheria-tetanuspertussis (DTP)-containing vaccine, leaving them vulnerable to deadly diseases. An article published by Oxford Academy examined India’s Intensified Mission Indradhanush (IMI) to understand the clinical and cost impact of vaccination strategies aimed at improving coverage and reaching zero-dose children.

The Urgent Need for Enhanced Vaccine Coverage

The COVID-19 pandemic has exacerbated a decade-long stagnation in vaccine coverage, threatening to reverse hard-won gains in child health. The global Immunisation Agenda 2030 is ambitious and necessitates an assessment of the cost-effectiveness of different strategies to boost immunisation rates. We can use various tactics such as supply-side initiatives and demand-side strategies. Supply-side initiatives may include training health workers or increasing vaccine delivery sites. On the other hand, demand-side strategies could involve raising awareness or offering incentives. India has the world’s largest immunisation program, supporting almost 26 million children annually.

Assessing Cost-Effectiveness: The Case of India’s IMI

A recent systematic review found that improving immunisation coverage can be cost-effective, with estimates ranging from 1.00 USD per child vaccinated against hepatitis B at birth in Indonesia to 161.95 USD per child vaccinated with DTP in Uttar Pradesh, India. This study narrows on the Intensified Mission Indradhanush, a periodic intensification of routine immunisation (PIRI) in India. This large-scale intervention aimed to bridge the immunisation gap, targeting an estimated six million children. The study’s findings suggest that IMI was not only impactful in reducing the number of zero-dose children but also proved to be cost-effective, a crucial consideration for resource-limited settings.

The Economics of Scaling Up Immunisation Efforts

As coverage expands, the costs associated with reaching the unvaccinated escalate. This study found that the incremental cost per dose delivered through IMI was more than double the cost of routine vaccine delivery. Moreover, districts with higher baseline coverage had higher incremental costs per dose administered using IMI. This raises questions about the sustainability and budgeting for such interventions, especially as the hardest-to-reach populations require more resources to vaccinate.

Towards a Cost-Effective Future in Vaccination

The study’s insights into IMI’s cost-effectiveness does provide hope for future vaccination strategies. However, the complexity of scaling up immunisation services necessitates continued research, especially in the design of social mobilisation efforts and the targeting of resources to maximise impact. One way to enhance the cost-effectiveness of IMI is to target program resources to children who would not otherwise receive routine vaccination services. The data reveals that up to 63% of children reached in this study were “incremental” and would not have been vaccinated without IMI. In contrast, about 37% of children immunised during IMI sessions were not incremental and would have been vaccinated regardless of IMI implementation.

Conclusion

The Intensified Mission Indradhanush stands as a testament to the potential of well-designed immunisation strategies to be both impactful and cost-effective. The application of PIRI at a large scale proved to be cost-effective. While cost-effectiveness varies based on implementation methods, scale, and context, PIRI interventions may be a cost-effective option to boost immunisation coverage, zero-dose children, and child health improvements. As the world strives towards the Immunisation Agenda 2030 goals, the lessons learned from IMI can inform future efforts to secure the health of children globally.

Reference url

Recent Posts

oral health Africa
    

Oral Health in Africa: Promoting Collaborative Solutions

🦷 Is oral health taking a back seat in public health discussions in Africa?

A new article reveals alarming statistics about the high prevalence of untreated dental diseases across the continent and a critical shortage of oral health professionals. It emphasizes the urgent need for collaborative action among healthcare providers and policy-makers to integrate oral health into broader public health frameworks.

Discover how strengthening partnerships can pave the way for improved health outcomes and resource allocation in oral health.

#SyenzaNews #globalhealth #HealthEconomics

tislelizumab NSCLC treatment
        

Early Benefit Assessment of Tislelizumab NSCLC Treatment: Insights and Implications

🧐 How is the evolving treatment landscape for NSCLC affecting patient access to tislelizumab?

The German Federal Joint Committee (G-BA) has launched an early benefit assessment for tislelizumab as a second-line treatment for adults with advanced NSCLC. This assessment notably focuses on PD-L1 negative patients and highlights the need for additional data to substantiate its value amidst a shifting emphasis on first-line immunotherapy.

Explore the nuances of this assessment and its implications for future research and market access in the full article.

#SyenzaNews #oncology #MarketAccess

colorectal cancer screening
    

Advances in Colorectal Cancer Screening: Access and Cost

🚀 Is blood-based screening redefining colorectal cancer detection?

The Shield blood test offers a non-invasive alternative to colonoscopy—boosting screening uptake, but raising questions around effectiveness and value.

🔍 Discover how this innovation could reshape patient care, payer strategy, and health system costs.

#SyenzaNews #HealthcareInnovation #CostEffectiveness #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.